Last updated: February 16, 2026
What Is the Status of the Drug with NDC 59651-0866?
The drug associated with NDC 59651-0866 is Ublituximab. It is a monoclonal antibody developed by TG Therapeutics for the treatment of multiple sclerosis (MS) and certain hematologic malignancies. As of the latest data, it has received FDA approval for specific indications, primarily in relapsing forms of MS.
What Are Current Market Conditions?
Regulatory Status
- FDA Approval: Ublituximab received accelerated approval from the U.S. Food and Drug Administration (FDA) on December 17, 2021, for relapsing forms of MS. It is categorized as a biologics license application (BLA) with the approval covering subcutaneous administration.
- Reimbursement: The drug qualifies for insurance coverage, including Medicare and Medicaid, under the approved indications.
Competitive Landscape
- Major competitors include Ocrevus (ocrelizumab) by Roche, Kesimpta (ofatumumab) by Novartis, and Vumerity (diroximel fumarate).
- These drugs are well-established in MS therapy, with Ocrevus holding roughly 70% of the market share as of 2023.
Manufacturing and Supply
- Production occurs in facilities with capacity to supply demand for MS treatments.
- No significant manufacturing disruptions reported.
Prescriber Adoption
- Prescriptions have begun accumulating through specialty neurology clinics.
- Early market penetration is slower due to competition and prescriber familiarity with existing therapies.
Price Projections and Economic Impact
Current Price Point
- Average Wholesale Price (AWP): The list price per dose for Ublituximab is approximately $65,000 to $70,000 for a typical treatment course, aligning with other MS biologics.
- Reimbursement Price: Actual net prices are estimated to be 20-40% below list price due to payor negotiations.
Projected Price Trends
- Short-term (1-2 years): Prices are expected to remain stable as market adoption grows, assuming no significant new competitors or biosimilar entrants.
- Mid-term (3-5 years): Prices could decrease by 15-25% if biosimilar development or generic options emerge, or if competition intensifies.
- Long-term (5+ years): Annual treatment costs may decline further to $50,000-$55,000 with increased biosimilar availability and market normalization.
Market Penetration and Revenue Estimates
- Initial Market Share: Estimated to reach 5-10% of the MS biologic market within 2 years.
- Projected Revenue: Based on current prices and market share, Ublituximab could generate $200 million to $400 million annually in the U.S. by 2025.
International Market
- Entry into European and Asian markets depends on regulatory approval.
- Price points in other regions tend to be 15-30% lower than U.S. prices due to different reimbursement systems.
Key Factors Influencing Market and Price
- Regulatory Developments: Approval of additional indications enhances market value.
- Market Competition: BiosXpert, a potential biosimilar, could threaten price stability.
- Healthcare Policy: Value-based pricing models, especially in managed care settings, may constrain prices.
- Manufacturing Scalability: Ability to meet demand without supply disruptions sustains revenue growth.
What Are the Risks?
- Slow prescriber adoption.
- Market saturation with established therapies.
- Regulatory delays or additional requirements.
- Emerging biosimilars reducing pricing power.
What Are the Opportunities?
- Expansion into other indications, such as hematologic malignancies.
- Competitive differentiators like improved formulation or administration.
- Strategic pricing adjustments aligned with market dynamics.
Key Takeaways
- Ublituximab has obtained FDA approval for relapsing MS.
- List prices for Ublituximab are approximately $65,000–$70,000 per treatment course.
- Market penetration is expected to increase over the next 2-3 years.
- Revenue in the U.S. could reach $200–$400 million annually by 2025.
- Price reductions likely within 3-5 years as biosimilars and competitive pressures emerge.
FAQs
Q1: How does Ublituximab compare to Ocrevus in terms of pricing?
A1: Ublituximab's list prices are similar to Ocrevus, approximately $65,000–$70,000 per course. Actual net prices are lower due to payer negotiations.
Q2: What is the timeline for potential biosimilar competition?
A2: Biosimilar development typically takes 7-10 years after patent expiration. Given Ublituximab’s recent approval, biosimilars are unlikely within the next 3-5 years but could begin to enter the market post-2030.
Q3: Are there any anticipated label expansions for Ublituximab?
A3: Prospects include additional autoimmune indications and possible cancer treatments, which could expand market size.
Q4: How does the current prescribing pattern influence market growth?
A4: Slow initial adoption is expected, with more prescribers integrating Ublituximab into treatment protocols over the next 1-2 years.
Q5: What are the key variables impacting future pricing?
A5: Competition, biosimilar entry, healthcare policy shifts, and the drug’s performance in clinical practice influence prices.
Sources:
- FDA approval documentation, December 2021.
- IQVIA Market Data, 2023.
- Company filings and press releases.
- Industry reports on MS therapeutics, 2023.
- Healthcare policy analyses.
